Evidence map›Paper›PMID 38216195›Full record

SynthesisBMJ open2024

Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.

Xiaoyan Liu, Feifei Wu, Wu Ye, Jili Deng, Mengmeng Zhang, Congli Zhang, Qingfeng Yu, Li Cao, Silin Gan, Jie Ma

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Xiaoyan LiuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Feifei WuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wu YeDepartment of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Jili DengKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.
Mengmeng ZhangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Congli ZhangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Qingfeng YuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Li CaoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Silin GanDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jie MaDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China fccmaj2@zzu.edu.cn.ORCID 0000-0002-5582-5398
First Affiliated Hospital of Zhengzhou University · CNPeking University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMultiple myeloma (MM) is a malignant plasma cell disorder. The most widely accepted staging system for MM is the revised International Staging System based on cytogenetic and clinical biomarkers. The circulating clonal plasma cells (CPCs) were reported to have potential prognostic impact on MM. Among various diagnostic approaches, multiparametric flow cytometry (FCM) offers heightened sensitivity, minimal invasiveness and reproducibility. We conducted a meta-analysis to evaluate the prognostic value of quantifying CPCs via FCM in newly diagnosed symptomatic MM (NDMM) patients.

designSystematic review and meta-analysis. DATA SOURCE: PubMed, Web of Science, Embase and references of included studies. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We included observational studies that evaluated the prognostic value of CPCs detected by FCM in NDMM. DATA EXTRACTION AND SYNTHESIS: Data were screened and extracted independently by two investigators. The pooled results originated from random effects models. The primary endpoint was overall survival (OS). The secondary endpoint was progression-free survival (PFS). To evaluate the prognostic value of CPCs in NDMM, HRs and their 95% CI for both OS and PFS were derived using COX multivariable models. These values were then used to compute the pooled estimated effect.

resultsOur meta-analysis encompassed a total of 2704 NDMM patients from 11 studies up to 27 August 2022. The pooled HR for OS and PFS in CPC-positive (CPCs+) group and CPC-negative group were 1.95 (95% CI 1.24 to 3.07) and 2.07 (95% CI 1.79 to 2.39), respectively. The autologous stem cell transplantation (ASCT) failed to eliminate the adverse impact on OS and PFS. The heterogeneity may stem from the use of novel agents or traditional chemotherapy as initial treatment.

conclusionThis meta-analysis indicates CPCs+ had an adverse impact on the prognosis of NDMM patients in the total population, and the adverse impact could not be eliminated by ASCT. PROSPERO REGISTRATION NUMBER: CRD42021272381.

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaFlow CytometryHumansPlasma CellsPrognosisReproducibility of ResultsTransplantation, AutologousHAEMATOLOGYMyelomaPrognosis

Identifiers

PMID38216195
PMCPMC10810043
OpenAlexW4390796683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.